11th Dec 2020 20:33
PureTech Health PLC - Boston, Massachusetts-based biotherapeutics company - Initiates phase one clinical trial of wholly-owned candidate LYT-200 for the potential treatment of metastatic solid tumors that are difficult to treat and have poor survival rates.
"We are pleased to have initiated the Phase 1 part of our LYT-200 clinical trial, which is a dose-finding portion designed to assess safety and tolerability and explore preliminary signals of efficacy for LYT-200," said Aleksandra Filipovic, head of oncology at PureTech. "We have generated compelling preclinical data to date, which we believe support the potential of LYT-200 as a new anti-cancer therapy targeting galectin-9, both as a single agent and in combination with other anti-cancer therapies."
Results are expected in the fourth quarter of 2021.
Current stock price: 315.00 pence
Year-to-date change: down 1.6%
By Lucy Heming;Â [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech